Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 9/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11615908 | 0.98 | ADRB2 (0.55) | ADRB2PTGS2CYP3A4GPR84TSHR | |
| SCHEMBL68546 | 0.98 | ADRB2 (0.55) | ADRB2PTGS2CYP3A4GPR84TSHR | |
| SCHEMBL68950 | 0.98 | ADRB2 (0.55) | ADRB2PTGS2CYP3A4GPR84TSHR | |
| SCHEMBL11808633 | 0.98 | ADRB2 (0.55) | ADRB2PTGS2CYP3A4GPR84TSHR | |
| SCHEMBL11737358 | 0.98 | ADRB2 (0.55) | ADRB2PTGS2CYP3A4GPR84TSHR | |
| SCHEMBL5916413 | 0.94 | ADRB2 (0.56) | ADRB2PTGS2CYP3A4GPR84TSHR | |
| SCHEMBL5916418 | 0.85 | ADRB2 (0.46) | ADRB2PTGS2CYP3A4TSHRHIF1A | |
| SCHEMBL14259760 | 0.84 | ADRB2 (0.47) | ADRB2PTGS2GPR84TSHRHIF1A | |
| SCHEMBL6535876 | 0.81 | ADRB2 (0.42) | ADRB2PTGS2CYP3A4TSHRHIF1A | |
| SCHEMBL1838599 | 0.81 | GPR84 (0.41) | ADRB2GPR84KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562038-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus | YALE UNIVERSITY (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2479203-A1 | AROMATIC POLYESTER | Muroran Institute of Technology (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120172570-A1 | AROMATIC POLYESTER | NITTA CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-8129493-B2 | Aromatic polyester | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | MURORAN INSTITUTE OF TECHNOLOGY (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110092662-A1 | AROMATIC POLYESTER | NITTA CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20060183922-A1 | CB2-selective cannabinoid derivatives | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-17 | — | — | US | disclosed |
| US-4025630-A | Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication | ABBOTT LABORATORIES (US) | 1977-05-24 | — | — | US | disclosed |
| US-4024275-A | Method of reducing elevated blood pressure with dihydroxy-hexahydrodibenzo(b,d)pyrans | ELI LILLY AND COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
| US-3972880-A | TRANQUILIZER | SHARPS ASSOCIATES (US) | 1976-08-03 | — | — | US | disclosed |
| US-3968125-A | Dihydroxyhexahydrodibenzo[b,d]pyrans | ELI LILLY AND COMPANY (US) | 1976-07-06 | — | — | US | disclosed |
| US-3962448-A | CNS DEPRESSANTS, VETERINARY | SMITHKLINE CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
| US-3960871-A | ANTIDEPRESSANT, ANALGESICS, ANTICONVULSANT ANTI-ANXIETY ACTIVITY | SHARPS ASSOCIATES (US) | 1976-06-01 | — | — | US | disclosed |
| US-3940421-A | Intermediates for the preparation of thienobenzopyrans and thiopyranobenzopyrans | ARTHUR D. LITTLE, INC. (US) | 1976-02-24 | — | — | US | disclosed |
| US-3931232-A | 3-Alkyl xanthene compounds | SMITHKLINE CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224343-A1 | MODIFIER FOR AROMATIC POLYESTER AND AROMATIC POLYESTER RESIN COMPOSITION COMPRISING THE SAME | F12, PHAX, WDR82 | ADRB2 1430/4885PTGS2 2866/4885CYP3A4 2028/4885 |
| US-20060183922-A1 | CB2-selective cannabinoid derivatives | CNR2, CNR1, GPR18 | ADRB2 64/4885PTGS2 244/4885CYP3A4 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.